AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31701891 — intervention group
Group type: EXPERIMENTAL
Intervention: Sphenopalatine ganglion stimulation
Number of subjects: 93
Study 31701891 — intervention group
Group type: COMPARATOR
Intervention: Sham control (cutaneous electrical stimulation)
Number of subjects: 93
Study 28815560 — intervention group
Group type: EXPERIMENTAL
Intervention: Lindioil ointment containing 200 μg g‐1 of indirubin
Number of subjects: 0
Study 28815560 — intervention group
Group type: EXPERIMENTAL
Intervention: Lindioil ointment containing 100 μg g‐1 of indirubin
Number of subjects: 0
Study 28815560 — intervention group
Group type: EXPERIMENTAL
Intervention: Lindioil ointment containing 50 μg g‐1 of indirubin
Number of subjects: 0
Study 28815560 — intervention group
Group type: EXPERIMENTAL
Intervention: Lindioil ointment containing 10 μg g‐1 of indirubin
Number of subjects: 0
Study 26693802 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibration Training (VT) targeting lower limb muscles, frequency 30-50 Hz, three times per week until discharge, amplitude increased from 2 to 5 mm
Number of subjects: 56
Study 26693802 — intervention group
Group type: COMPARATOR
Intervention: Usual care physiotherapy sessions
Number of subjects: 56
Study 24140226 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 180
Study 24140226 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressants (MED)
Number of subjects: 180
Study 24140226 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined CBT and antidepressants (COMB)
Number of subjects: 180
Study 24140226 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard treatment (ST)
Number of subjects: 180
Study 22648221 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment A (novel anti-acne/anti-aging formulation)
Number of subjects: 0
Study 22648221 — intervention group
Group type: COMPARATOR
Intervention: Treatment B (tretinoin cream 0.025%)
Number of subjects: 0
Study 19780041 — intervention group
Group type: EXPERIMENTAL
Intervention: Caloric air stimulation of the right ear
Number of subjects: 10
Study 19780041 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 10
Study 18666803 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan therapy for 9 weeks
Number of subjects: 60
Study 18666803 — intervention group
Group type: COMPARATOR
Intervention: Placebo therapy for 9 weeks
Number of subjects: 60
Study 16613662 — intervention group
Group type: EXPERIMENTAL
Intervention: Gallium nitrate 200 mg/m2 daily for 5 days
Number of subjects: 64
Study 16613662 — intervention group
Group type: COMPARATOR
Intervention: Pamidronate 60 mg (increased to 90 mg for initial serum calcium > or = 13.5 mg/dL) followed by placebo infusions for 4 days
Number of subjects: 64
Study 16613662 — intervention group
Group type: COMPARATOR
Intervention: Pamidronate 90 mg for initial serum calcium > or = 13.5 mg/dL
Number of subjects: 64
Study 16613662 — intervention group
Group type: COMPARATOR
Intervention: Pamidronate 60 mg for initial serum calcium > or = 13.5 mg/dL
Number of subjects: 64
Study 16613662 — intervention group
Group type: EXPERIMENTAL
Intervention: Gallium nitrate for initial serum calcium > or = 13.5 mg/dL
Number of subjects: 64
Study 16613662 — intervention group
Group type: COMPARATOR
Intervention: Pamidronate
Number of subjects: 64
Study 16613662 — intervention group
Group type: EXPERIMENTAL
Intervention: Gallium nitrate
Number of subjects: 64
Study 16613662 — intervention group
Group type: COMPARATOR
Intervention: Pamidronate (responders)
Number of subjects: 64
Study 16613662 — intervention group
Group type: EXPERIMENTAL
Intervention: Gallium nitrate (responders)
Number of subjects: 64
Study 14616318 — intervention group
Group type: EXPERIMENTAL
Intervention: Mivacurium (0.1 mg kg‐1 bolus followed by continuous infusion)
Number of subjects: 32
Study 14616318 — intervention group
Group type: COMPARATOR
Intervention: Comparison with phenotypically normal patients (UU)
Number of subjects: 32
Study 11018164 — intervention group
Group type: EXPERIMENTAL
Intervention: long-long regimen (zidovudine starting at 28 weeks' gestation, 6 weeks treatment in infant)
Number of subjects: 1437
Study 11018164 — intervention group
Group type: EXPERIMENTAL
Intervention: long-short regimen (zidovudine starting at 28 weeks' gestation, 3 days treatment in infant)
Number of subjects: 1437
Study 11018164 — intervention group
Group type: EXPERIMENTAL
Intervention: short-long regimen (zidovudine starting at 35 weeks' gestation, 6 weeks treatment in infant)
Number of subjects: 1437
Study 11018164 — intervention group
Group type: COMPARATOR
Intervention: short-short regimen (zidovudine starting at 35 weeks' gestation, 3 days treatment in infant)
Number of subjects: 1437
Study 11018164 — intervention group
Group type: EXPERIMENTAL
Intervention: in utero transmission (short regimens)
Number of subjects: 1437
Study 11018164 — intervention group
Group type: EXPERIMENTAL
Intervention: in utero transmission (long regimens)
Number of subjects: 1437
Study 8842912 — intervention group
Group type: EXPERIMENTAL
Intervention: Single syringe method
Number of subjects: 5
Study 8842912 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed gravity drainage system
Number of subjects: 5
Study 8842912 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed double syringe method
Number of subjects: 5
Study 8842912 — intervention group
Group type: COMPARATOR
Intervention: Control (no lavage)
Number of subjects: 5
Study 10148407 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotorest Kinetic Treatment Table
Number of subjects: 100
Study 10148407 — intervention group
Group type: COMPARATOR
Intervention: Traditional hospital bed
Number of subjects: 100
Study 6660456 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral position after bupivacaine administration
Number of subjects: 70
Study 6660456 — intervention group
Group type: COMPARATOR
Intervention: Supine position after bupivacaine administration
Number of subjects: 70
Study 6660456 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral position
Number of subjects: 70
Study 6660456 — intervention group
Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 70
Study 31533841 — intervention group
Group type: EXPERIMENTAL
Intervention: Audit and feedback with action implementation toolbox
Number of subjects: 21
Study 31533841 — intervention group
Group type: COMPARATOR
Intervention: Audit and feedback only (without toolbox)
Number of subjects: 21
Study 29998882 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated Interferon (Peg-IFN) for 48 weeks
Number of subjects: 162
Study 29998882 — intervention group
Group type: COMPARATOR
Intervention: Entecavir (ETV) for 12 weeks followed by Peg-IFN for 48 weeks (sequential treatment)
Number of subjects: 162
Study 27154394 — intervention group
Group type: EXPERIMENTAL
Intervention: Enterovirus quantity at the time of OPV administration
Number of subjects: 0
Study 27154394 — intervention group
Group type: EXPERIMENTAL
Intervention: Enterovirus quantity
Number of subjects: 0
Study 25261378 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled Temperature Chain (CTC; up to 40 °C for <30 days)
Number of subjects: 2128
Study 25261378 — intervention group
Group type: COMPARATOR
Intervention: Standard Cold Chain (SCC; 2‐8 °C)
Number of subjects: 2128
Study 23167789 — intervention group
Group type: EXPERIMENTAL
Intervention: Midwall EF in LVH group (42.8±4.4%)
Number of subjects: 60
Study 23167789 — intervention group
Group type: EXPERIMENTAL
Intervention: Midwall FS in LVH group (13.4±2.8%)
Number of subjects: 60
Study 23167789 — intervention group
Group type: EXPERIMENTAL
Intervention: EF in LVH group
Number of subjects: 60
Study 23167789 — intervention group
Group type: EXPERIMENTAL
Intervention: Midwall EF correlation with LVMI
Number of subjects: 60
Study 23167789 — intervention group
Group type: EXPERIMENTAL
Intervention: Midwall FS correlation with LVMI
Number of subjects: 60
Study 20102858 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (family-centered program with 12 sessions of behavioral curriculum, dietary advice from a registered dietitian weekly for the first 3 months and monthly thereafter, and monthly consultations with a primary care physician)
Number of subjects: 76
Study 20102858 — intervention group
Group type: COMPARATOR
Intervention: Control group (monthly consultations with a primary care physician who received brief training on obesity)
Number of subjects: 76
Study 20102858 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 76
Study 20102858 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 76
Study 16787761 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% diclofenac gel
Number of subjects: 42
Study 16787761 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 16787761 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac tablets
Number of subjects: 42
Study 16787761 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol tablets
Number of subjects: 42
Study 16095062 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg oral tramadol
Number of subjects: 20
Study 16095062 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 12386639 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone alone (0.3 mg/kg)
Number of subjects: 5
Study 12386639 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem alone (180 mg)
Number of subjects: 5
Study 12386639 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone-diltiazem combination
Number of subjects: 5
Study 12386639 — intervention group
Group type: COMPARATOR
Intervention: Methylprednisolone alone
Number of subjects: 5
Study 10646171 — intervention group
Group type: EXPERIMENTAL
Intervention: Clustered sleep fragmentation (every 30 s for 30 min every 90 min)
Number of subjects: 16
Study 10646171 — intervention group
Group type: COMPARATOR
Intervention: Regular sleep fragmentation (every 90 s)
Number of subjects: 16
Study 7845114 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed intrope therapy (PIT) with dobutamine, infused to raise heart rate to 70-80% maximum for 30 min per day, 4 days per week for 3 weeks
Number of subjects: 10
Study 7845114 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed intrope therapy (PIT) with dobutamine
Number of subjects: 10
Study 7845114 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 10
Study 2347075 — intervention group
Group type: EXPERIMENTAL
Intervention: High water content non‐HEMA (ofilcon A) lens (Durasoft 4; Wesley‐Jessen)
Number of subjects: 20
Study 2347075 — intervention group
Group type: COMPARATOR
Intervention: Mid‐water content modified HEMA material
Number of subjects: 20
Study 2347075 — intervention group
Group type: COMPARATOR
Intervention: Low water content HEMA and non‐HEMA materials
Number of subjects: 20
Study 44632 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunitrazepam (2 mg on the night before operation followed by 2 mg on the morning of operation)
Number of subjects: 81
Study 44632 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study 44632 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunitrazepam
Number of subjects: 81
Study 44632 — intervention group
Group type: COMPARATOR
Intervention: Flunitrazepam and Placebo
Number of subjects: 81
Study 30874457 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 132
Study 30874457 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132
Study 28655302 — intervention group
Group type: EXPERIMENTAL
Intervention: Reusable sanitary pads
Number of subjects: 27
Study 28655302 — intervention group
Group type: EXPERIMENTAL
Intervention: Puberty education
Number of subjects: 27
Study 28655302 — intervention group
Group type: EXPERIMENTAL
Intervention: Education with reusable sanitary pads
Number of subjects: 27
Study 28655302 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 27
Study 25885963 — intervention group
Group type: EXPERIMENTAL
Intervention: Tight glucose control
Number of subjects: 1114
Study 25885963 — intervention group
Group type: COMPARATOR
Intervention: SHINE design
Number of subjects: 1114
Study 25885963 — intervention group
Group type: COMPARATOR
Intervention: Goldilocks design
Number of subjects: 1114
Study 23506216 — intervention group
Group type: EXPERIMENTAL
Intervention: NeuroAiD (four capsules three times daily for three months)
Number of subjects: 1100
Study 23506216 — intervention group
Group type: COMPARATOR
Intervention: Placebo (four capsules three times daily for three months)
Number of subjects: 1100
Study 21298400 — intervention group
Group type: EXPERIMENTAL
Intervention: Mujeres en Accion intervention
Number of subjects: 0
Study 21298400 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 19616774 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative pressure wound therapy (NPWT)
Number of subjects: 24
Study 19616774 — intervention group
Group type: COMPARATOR
Intervention: Standard wound dressing
Number of subjects: 24
Study 17846459 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback on daily step counts (monitoring and recording step counts during week 1)
Number of subjects: 105
Study 17846459 — intervention group
Group type: COMPARATOR
Intervention: No feedback condition (sealed pedometer during week 2)
Number of subjects: 105
Study 15025611 — intervention group
Group type: EXPERIMENTAL
Intervention: 27-G (0.41 mm) Quincke spinal needle
Number of subjects: 676
Study 15025611 — intervention group
Group type: EXPERIMENTAL
Intervention: 27-G (0.41 mm) Whitacre spinal needle
Number of subjects: 676
Study 15025611 — intervention group
Group type: COMPARATOR
Intervention: Both Quincke and Whitacre spinal needles
Number of subjects: 676
Study 11570932 — intervention group
Group type: EXPERIMENTAL
Intervention: music‐assisted reframing intervention
Number of subjects: 40
Study 11570932 — intervention group
Group type: COMPARATOR
Intervention: typical reframing intervention
Number of subjects: 40
Study 9748859 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary percutaneous coronary angioplasty (PTCA)
Number of subjects: 82
Study 9748859 — intervention group
Group type: COMPARATOR
Intervention: Intravenous thrombolysis
Number of subjects: 82
Study 7531457 — intervention group
Group type: EXPERIMENTAL
Intervention: P. carinii cluster ratios
Number of subjects: 96
Study 7531457 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythrosin B (vital stain for P. carinii viability)
Number of subjects: 96
Study 7531457 — intervention group
Group type: EXPERIMENTAL
Intervention: 35-45 kD antigen
Number of subjects: 96
Study 7531457 — intervention group
Group type: EXPERIMENTAL
Intervention: 95 kD antigen
Number of subjects: 96
Study 7531457 — intervention group
Group type: COMPARATOR
Intervention: 52 and 66 kD antigens
Number of subjects: 96
Study 3263599 — intervention group
Group type: EXPERIMENTAL
Intervention: Healon
Number of subjects: 60
Study 3263599 — intervention group
Group type: COMPARATOR
Intervention: Viscoat (irrigated/aspirated)
Number of subjects: 60
Study 3263599 — intervention group
Group type: COMPARATOR
Intervention: Viscoat (left in the eye)
Number of subjects: 60
Study 31491040 — intervention group
Group type: EXPERIMENTAL
Intervention: Levothyroxine (L-T4)
Number of subjects: 0
Study 31491040 — intervention group
Group type: EXPERIMENTAL
Intervention: Triiodothyronine (T3)
Number of subjects: 0
Study 31491040 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28733983 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab emtansine (T-DM1)
Number of subjects: 0
Study 28733983 — intervention group
Group type: COMPARATOR
Intervention: Treatment of physician's choice (TPC)
Number of subjects: 0
Study 26407753 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 5395
Study 26407753 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin followed by warfarin
Number of subjects: 5395
Study 23085329 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight management text-messages (2-5 messages per day)
Number of subjects: 52
Study 23085329 — intervention group
Group type: COMPARATOR
Intervention: Usual-care comparison group
Number of subjects: 52
Study 21763936 — intervention group
Group type: EXPERIMENTAL
Intervention: Rilpivirine (25 mg once daily)
Number of subjects: 690
Study 21763936 — intervention group
Group type: COMPARATOR
Intervention: Efavirenz (600 mg once daily)
Number of subjects: 690
Study 21763936 — intervention group
Group type: EXPERIMENTAL
Intervention: Rilpivirine
Number of subjects: 690
Study 21763936 — intervention group
Group type: COMPARATOR
Intervention: Efavirenz
Number of subjects: 690
Study 19427433 — intervention group
Group type: EXPERIMENTAL
Intervention: Low chronotropic index
Number of subjects: 920
Study 16766777 — intervention group
Group type: EXPERIMENTAL
Intervention: ExCHO - Subjects exercised on a cycle ergometer at 70% VO2peak with a net energy cost of 400 kcal, followed by consumption of a high carbohydrate (CHO) energy bar
Number of subjects: 8
Study 16766777 — intervention group
Group type: COMPARATOR
Intervention: NoExCHO - Subjects sat quietly rather than exercised, followed by consumption of a high carbohydrate (CHO) energy bar
Number of subjects: 8
Study 16766777 — intervention group
Group type: COMPARATOR
Intervention: NoExGlc - Subjects consumed a 50 g glucose (glc) drink as the reference CHO for GI and insulinemic index (II) determination
Number of subjects: 8
Study 15127867 — intervention group
Group type: EXPERIMENTAL
Intervention: Giomer composite
Number of subjects: 40
Study 15127867 — intervention group
Group type: COMPARATOR
Intervention: Microfilled composite
Number of subjects: 40
Study 11331845 — intervention group
Group type: EXPERIMENTAL
Intervention: Subfascial endoscopic division of incompetent perforating veins (SEPS)
Number of subjects: 39
Study 11331845 — intervention group
Group type: COMPARATOR
Intervention: Open subfascial division of incompetent perforating veins (Linton procedure)
Number of subjects: 39
Study 9154401 — intervention group
Group type: EXPERIMENTAL
Intervention: terbinafine (250 mg daily)
Number of subjects: 118
Study 9154401 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 118
Study 8097683 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (10‐15 mg plus 150 micrograms min‐1 kg‐1)
Number of subjects: 12
Study 8097683 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 12
Study 2892252 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 0
Study 2892252 — intervention group
Group type: EXPERIMENTAL
Intervention: Nizatidine
Number of subjects: 0
Study 2892252 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30498827 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein dairy-based products and energy-enriched berry purées for three months, providing nearly 300 kcal and 14 g protein per day.
Number of subjects: 85
Study 30498827 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified).
Number of subjects: 85
Study 26831176 — intervention group
Group type: EXPERIMENTAL
Intervention: Deworming regimen (DR)
Number of subjects: 615
Study 25113056 — intervention group
Group type: EXPERIMENTAL
Intervention: Unified Protocol for Transdiagnostic Treatment of Emotional Disorders (UP)
Number of subjects: 15
Study 23221739 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcifediol supplementation
Number of subjects: 217
Study 23221739 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcifediol supplementation with concomitant active vitamin D
Number of subjects: 217
Study 23221739 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcifediol supplementation in patients with suppressed baseline PTH
Number of subjects: 217
Study 20956208 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen (1 g TID for 2 weeks)
Number of subjects: 33
Study 20956208 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 18761644 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin detemir (0.4 U/kg)
Number of subjects: 32
Study 18761644 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin detemir (0.4 U/kg) in children (8-12 years)
Number of subjects: 32
Study 18761644 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin detemir (0.4 U/kg) in adolescents (13-17 years)
Number of subjects: 32
Study 18761644 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine (0.4 U/kg)
Number of subjects: 32
Study 15850630 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised intake of artemether-lumefantrine (all doses observed with fatty-food intake; n=313)
Number of subjects: 957
Study 15850630 — intervention group
Group type: COMPARATOR
Intervention: Unsupervised intake of artemether-lumefantrine (first dose supervised followed by outpatient treatment with nutritional advice; n=644)
Number of subjects: 957
Study 12452220 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural ropivacaine + intravenous ketorolac
Number of subjects: 107
Study 12452220 — intervention group
Group type: COMPARATOR
Intervention: Intravenous ketorolac alone
Number of subjects: 107
Study 10777467 — intervention group
Group type: EXPERIMENTAL
Intervention: Platinum-based combination chemotherapy administered sequentially or concurrently with thoracic radiation therapy
Number of subjects: 0
Study 10777467 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic radiation therapy combined with novel drugs or new drug combinations
Number of subjects: 0
Study 10777467 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel and carboplatin in combination with thoracic radiation therapy
Number of subjects: 0
Study 10777467 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined modality therapy with thoracic radiation therapy
Number of subjects: 0
Study 9105526 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine (10 mg)
Number of subjects: 12
Study 9105526 — intervention group
Group type: EXPERIMENTAL
Intervention: Loratadine (10 mg)
Number of subjects: 12
Study 9105526 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 8245373 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intervention group (n = 328)
Number of subjects: 652
Study 8245373 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 324)
Number of subjects: 652
Study 3698062 — intervention group
Group type: EXPERIMENTAL
Intervention: Diflunisal
Number of subjects: 40
Study 3698062 — intervention group
Group type: COMPARATOR
Intervention: Acetaminophen with codeine
Number of subjects: 40
Study 30081868 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth YWC
Number of subjects: 0
Study 30081868 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-to-face YWC
Number of subjects: 0
Study 30081868 — intervention group
Group type: COMPARATOR
Intervention: HIV counseling and testing (HCT)
Number of subjects: 0